Cargando…
The Rationale for Insulin Therapy in Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia, with a prevalence that increases with age. By 2050, the worldwide number of patients with AD is projected to reach more than 140 million. The prominent signs of AD are progressive memory loss, accompanied by a gradual decline in cognitive...
Autor principal: | Ribarič, Samo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6273626/ https://www.ncbi.nlm.nih.gov/pubmed/27240327 http://dx.doi.org/10.3390/molecules21060689 |
Ejemplares similares
-
Nanotechnology Therapy for Alzheimer′s Disease Memory Impairment Attenuation
por: Ribarič, Samo
Publicado: (2021) -
Peptides as Potential Therapeutics for Alzheimer’s Disease
por: Ribarič, Samo
Publicado: (2018) -
Detecting Early Cognitive Decline in Alzheimer’s Disease with Brain Synaptic Structural and Functional Evaluation
por: Ribarič, Samo
Publicado: (2023) -
Physical Exercise, a Potential Non-Pharmacological Intervention for Attenuating Neuroinflammation and Cognitive Decline in Alzheimer’s Disease Patients
por: Ribarič, Samo
Publicado: (2022) -
Unfolded Protein Response and Macroautophagy in Alzheimer’s, Parkinson’s and Prion Diseases
por: Milisav, Irina, et al.
Publicado: (2015)